US Stock Insider Trading | Schrodinger disclosed 3 insider transactions on February 12

K-LinePoet · 2026-03-04T00:15:03+00:00

On February 12, 2026, Schrodinger disclosed that several executives conducted stock sale transactions on February 10, including Lorton Kenneth Patrick, Herman Jenny, and Tran Yvonne, involving a total of over 2,500 shares. The company focuses on developing computing platforms for efficient drug discovery and materials applications.

K-LinePoet

2026-03-04 00:15:03

Abstract generation in progress

On February 12, 2026, Schrodinger (SDGR) disclosed three insider trading transactions. Executive Lorton Kenneth Patrick sold 925 shares on February 10, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 12, 2026	Executive	Herman Jenny	February 10, 2026	Sell	752	13.79	$13,800
February 12, 2026	Executive	Tran Yvonne	February 10, 2026	Sell	776	13.80	$13,800
February 12, 2026	Executive	Lorton Kenneth Patrick	February 10, 2026	Sell	925	13.73	$13,700
February 11, 2026	Executive	Abel Robert Lorne	February 9, 2026	Sell	1,230	13.51	$16,600
October 17, 2025	Executive	Dugan Margaret	October 16, 2025	Sell	1,395	21.07	$29,400
April 15, 2025	Executive	Akinsanya Karen	April 14, 2025	Sell	3,345	25.00	$83,600
April 15, 2025	Executive	Akinsanya Karen	April 14, 2025	Buy	3,345	2.92	$9,767.40
April 15, 2025	Executive	Akinsanya Karen	April 14, 2025	Buy	13,400	3.22	$43,100
April 15, 2025	Executive	Akinsanya Karen	April 14, 2025	Sell	5,000	25.11	$125,600
April 15, 2025	Executive	Akinsanya Karen	April 14, 2025	Sell	8,378	25.11	$210,400

[Company Profile]

Schrodinger, Inc. was incorporated in California in August 1990 under applicable laws. The company has developed a physics-based computational platform capable of accurately predicting key molecular properties, enabling faster and lower-cost discovery of high-quality, novel molecules for drug development and materials applications. Their software is used by biopharmaceutical, industrial companies, academic institutions, and government laboratories worldwide. The company is a leading provider of computational software solutions for drug discovery, offering various software tools to accelerate all stages of molecule discovery, design, and optimization. They also leverage their platform and capabilities through a series of collaborations and wholly owned drug discovery programs covering a broad range of disease targets and indications.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.